These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8854045)

  • 21. Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins.
    Di Braccio M; Grossi G; Roma G; Grazia Signorello M; Leoncini G
    Eur J Med Chem; 2004 May; 39(5):397-409. PubMed ID: 15110966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and in vitro activities on anti-platelet aggregation of 4-methoxybenzene-1,3-isophthalamides.
    Liu XJ; Shi XX; Zhong YL; Liu N; Liu K
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6591-5. PubMed ID: 23010272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Synthesis and platelet aggregation inhibitory activity of analogues of 4-([2-(1H-imidazol-1-yl)-1-(4-substituted-phenyl)ethoxy]methyl)benzoic acids].
    Wu QY; Yang JQ
    Yao Xue Xue Bao; 1991; 26(10):741-6. PubMed ID: 1823715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyridazines. XVIII. 6-Aryl-3(2H)-pyridazinones inhibit calcium influx in stimulated platelets.
    Montero-Lastres A; Fraiz N; Laguna R; Cano E; Estevez I; Raviña E
    Biol Pharm Bull; 1999 Dec; 22(12):1376-9. PubMed ID: 10746173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of caffeic acid amide analogues as anti-platelet aggregation and anti-oxidative agents.
    Hung CC; Tsai WJ; Kuo LM; Kuo YH
    Bioorg Med Chem; 2005 Mar; 13(5):1791-7. PubMed ID: 15698796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines.
    Ihmaid SK; Al-Rawi JM; Bradley CJ; Angove MJ; Robertson MN
    Eur J Med Chem; 2012 Nov; 57():85-101. PubMed ID: 23059543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and pharmacological evaluation of 4a-methyl-4,4a,5,6-tetrahydrothieno[2,3-h]cinnolin-3(2H)-ones.
    Pinna GA; Salis E; Berta D; Gavini E; D'Amico M
    Farmaco; 1997 Jan; 52(1):29-33. PubMed ID: 9181678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and inhibition of platelet aggregation for some 1-o-chlorophenyl-1,2,3,4-tetrahydroisoquinoline derivatives.
    Yang J; Hua WY; Wang FX; Wang ZY; Wang X
    Bioorg Med Chem; 2004 Dec; 12(24):6547-57. PubMed ID: 15556771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New pyridazino[4,5-b]indole derivatives with inodilator and antiaggregatory activities.
    Monge A; Aldana I; Losa MJ; Font M; Cenarruzabeitia E; Castiella E; Frechilla D; Santiago E; Martínez de Irujo JJ; Alberdi E
    Arzneimittelforschung; 1993 Nov; 43(11):1175-80. PubMed ID: 8292060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyridazine derivatives 32: Stille-based approaches in the synthesis of 5-substituted-6-phenyl-3(2H)-pyridazinones.
    Sotelo E; Coelho A; Raviña E
    Chem Pharm Bull (Tokyo); 2003 Apr; 51(4):427-30. PubMed ID: 12672999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as platelet aggregation inhibitors.
    Tian X; Wang LY; Xia S; Li ZB; Liu XH; Yuan Y; Fang L; Zuo H
    Bioorg Med Chem Lett; 2012 Jan; 22(1):204-6. PubMed ID: 22137848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
    Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
    Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Synthesis and evaluation of the aldose reductase inhibitory activity of new diaryl pyridazine-3-ones].
    Coudert P; Duroux E; Bastide P; Couquelet J; Tronche P
    J Pharm Belg; 1991; 46(6):375-80. PubMed ID: 1783971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
    Dal Piaz V; Giovannoni MP; Castellana C; Palacios JM; Beleta J; Doménech T; Segarra V
    J Med Chem; 1997 May; 40(10):1417-21. PubMed ID: 9154964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
    Gordge MP; Hothersall JS; Noronha-Dutra AA
    Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
    Hutchinson JH; Cook JJ; Brashear KM; Breslin MJ; Glass JD; Gould RJ; Halczenko W; Holahan MA; Lynch RJ; Sitko GR; Stranieri MT; Hartman GD
    J Med Chem; 1996 Nov; 39(23):4583-91. PubMed ID: 8917647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity.
    Wang WY; Hsieh PW; Wu YC; Wu CC
    Biochem Pharmacol; 2007 Aug; 74(4):601-11. PubMed ID: 17601492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
    Harris RR; Black L; Surapaneni S; Kolasa T; Majest S; Namovic MT; Grayson G; Komater V; Wilcox D; King L; Marsh K; Jarvis MF; Nuss M; Nellans H; Pruesser L; Reinhart GA; Cox B; Jacobson P; Stewart A; Coghlan M; Carter G; Bell RL
    J Pharmacol Exp Ther; 2004 Dec; 311(3):904-12. PubMed ID: 15277581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyran derivatives XIX. (Dialkylamino) substituted 1-benzopyranones and naphthopyranones with platelet antiaggregating activity.
    Di Braccio M; Roma G; Leoncini G; Poggi M
    Farmaco; 1995 Oct; 50(10):703-11. PubMed ID: 8590578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.
    Egbertson MS; Cook JJ; Bednar B; Prugh JD; Bednar RA; Gaul SL; Gould RJ; Hartman GD; Homnick CF; Holahan MA; Libby LA; Lynch JJ; Lynch RJ; Sitko GR; Stranieri MT; Vassallo LM
    J Med Chem; 1999 Jul; 42(13):2409-21. PubMed ID: 10395482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.